Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 9 |
| List of Tables | 8 | 3 |
| List of Figures | 11 | 2 |
| Gastrointestinal Disorder Therapeutics Market: Introduction | 13 | 2 |
| Overview | 13 | 1 |
| GBI Research Report Guidance | 14 | 1 |
| Global Gastrointestinal Disorder Therapeutics Market: Market Characterization | 15 | 11 |
| Market Forecasts | 15 | 1 |
| Revenue | 15 | 1 |
| Global Generic Share | 16 | 1 |
| Annual Cost of Treatment (ACT) | 17 | 1 |
| Treatment Usage Patterns | 18 | 2 |
| Diseased Population | 20 | 1 |
| Treatment Seeking Population | 21 | 1 |
| Diagnosed Population | 22 | 1 |
| Treated Population | 23 | 1 |
| Drivers and Restraints for the Global Gastrointestinal Disorder Therapeutics Market | 24 | 1 |
| Market Drivers | 24 | 1 |
| Stable Increase in the Prevalence and Incidence Rates | 24 | 1 |
| Increase in Awareness Levels of Disease Progression and Etiology | 24 | 1 |
| Future Approval and Launch of Biologics | 24 | 1 |
| Market Restraints | 25 | 1 |
| Entry of Generics and Their Dominance in the Future | 25 | 1 |
| Lack of Definite Diagnosis and Low Diagnosis Rate | 25 | 1 |
| Presence of Serious Side Effects for Certain Classes of Therapeutic Drugs | 25 | 1 |
| Gastrointestinal Disorder Therapeutics Market: Geographical Landscape | 26 | 16 |
| Revenue Analysis by Geography | 26 | 2 |
| The US | 28 | 1 |
| Revenue | 28 | 1 |
| Annual Cost of Treatment | 29 | 1 |
| Treatment Usage Patterns | 30 | 1 |
| Diseased Population | 31 | 1 |
| Treatment Seeking Population | 31 | 1 |
| Diagnosed Population | 31 | 1 |
| Treated Population | 31 | 1 |
| Top Five Countries of Europe | 32 | 1 |
| Revenue | 32 | 1 |
| Revenue by Country | 33 | 2 |
| Annual Cost of Treatment | 35 | 1 |
| Treatment Usage Pattern | 36 | 1 |
| Diseased Population | 37 | 1 |
| Treatment Seeking Population | 37 | 1 |
| Diagnosed Population | 37 | 1 |
| Treated Population | 37 | 1 |
| Japan | 38 | 1 |
| Revenue | 38 | 1 |
| Annual Cost of Treatment | 39 | 1 |
| Treatment Usage Patterns | 40 | 1 |
| Diseased Population | 41 | 1 |
| Treatment Seeking Population | 41 | 1 |
| Diagnosed Population | 41 | 1 |
| Treated Population | 41 | 1 |
| Global Gastrointestinal Disorder Therapeutics Market: Therapeutic Landscape | 42 | 52 |
| Global Irritable Bowel Syndrome Therapeutics Market Forecasts | 42 | 1 |
| Introduction | 42 | 1 |
| Revenue | 43 | 1 |
| Generic Share | 44 | 1 |
| Revenue Analysis by Country | 45 | 2 |
| Annual Cost of Treatment | 47 | 1 |
| Treatment Flow Algorithm | 48 | 1 |
| Treatment Usage Patterns | 49 | 1 |
| Diseased Population | 50 | 1 |
| Treatment Seeking Population | 50 | 1 |
| Diagnosed Population | 50 | 1 |
| Treated Population | 50 | 1 |
| Marketed Products | 51 | 1 |
| Lotronex | 51 | 1 |
| Overview | 51 | 1 |
| Amitiza (Lubiprostone) | 51 | 1 |
| Overview | 51 | 1 |
| Bentyl (Dicyclomine hydrochloride) | 52 | 1 |
| Overview | 52 | 1 |
| Drivers and Restraints for the IBS Therapeutics Market | 53 | 1 |
| Drivers for the IBS Therapeutics Market | 53 | 1 |
| Launch of New Drugs with Novel Mechanism of Action | 53 | 1 |
| High Prevalence of the Disease | 53 | 1 |
| Restraints for the IBS Therapeutics Market | 53 | 1 |
| Low Treatment Seeking Rate Could Affect the Availability of Patients for Prescription | 53 | 1 |
| Lack of Definite Diagnostic Techniques Delays Treatments of IBS | 53 | 1 |
| Global Ulcerative Colitis Therapeutics Market Forecasts | 54 | 1 |
| Introduction | 54 | 1 |
| Revenue | 55 | 1 |
| Generic Share | 56 | 1 |
| Revenue Analysis by Country | 57 | 2 |
| Annual Cost of Treatment | 59 | 1 |
| Treatment Flow Algorithm | 60 | 1 |
| Treatment Usage Patterns | 61 | 1 |
| Diseased Population | 62 | 1 |
| Treatment Seeking Population | 63 | 1 |
| Diagnosed Population | 63 | 1 |
| Treated Population | 63 | 1 |
| Major Marketed Products | 64 | 1 |
| Asacol | 64 | 1 |
| Overview | 64 | 1 |
| Lialda | 64 | 1 |
| Overview | 64 | 1 |
| Pentasa | 64 | 1 |
| Overview | 64 | 1 |
| Apriso | 64 | 1 |
| Overview | 64 | 1 |
| Colazal | 64 | 1 |
| Overview | 64 | 1 |
| Remicade | 65 | 1 |
| Overview | 65 | 1 |
| Azulfidine | 65 | 1 |
| Overview | 65 | 1 |
| Drivers and Restraints for Ulcerative Colitis Therapeutics Market | 65 | 1 |
| Drivers for the Ulcerative Colitis Therapeutics Market | 66 | 1 |
| The Future Approval of Biologics will Drive the Market | 66 | 1 |
| Availability of Large Patient Pool will Increase the Market Revenue | 66 | 1 |
| Restraints for the Ulcerative Colitis Therapeutics Market | 66 | 1 |
| Diagnostic Limitations could Affect Market Growth | 66 | 1 |
| Complex Etiology of Ulcerative Colitis Makes the Diagnosis and Treatment of the Disease Difficult | 66 | 1 |
| Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecasts | 67 | 1 |
| Introduction | 67 | 1 |
| Revenue | 68 | 2 |
| Generic Share | 70 | 1 |
| Revenue Analysis by Country | 71 | 2 |
| Annual Cost of Treatment | 73 | 1 |
| Treatment Flow Algorithm | 74 | 2 |
| Treatment Usage Patterns | 76 | 1 |
| Diseased Population | 77 | 1 |
| Treatment Seeking Population | 77 | 1 |
| Diagnosed Population | 77 | 1 |
| Treated Population | 77 | 1 |
| Major Marleted Products | 78 | 1 |
| Nexium (esomeprazole) | 78 | 1 |
| Overview | 78 | 1 |
| Aciphex (rabeprazole sodium) | 78 | 1 |
| Overview | 78 | 1 |
| Prevacid (lansoprazole) | 78 | 1 |
| Overview | 78 | 1 |
| Prilosec (omeprazole) | 78 | 1 |
| Overview | 78 | 1 |
| Protonix (pantoprazole sodium) | 79 | 1 |
| Overview | 79 | 1 |
| Tagamet (cimetidine) | 79 | 1 |
| Overview | 79 | 1 |
| Pepcid (famotidine) | 79 | 1 |
| Overview | 79 | 1 |
| Zantac (ranitidine hydrochloride) | 79 | 1 |
| Overview | 79 | 1 |
| Axid (nizatidine) | 79 | 1 |
| Overview | 79 | 1 |
| Drivers and Restraints for the GERD Therapeutics Market | 80 | 1 |
| Drivers for the GERD Therapeutics Market | 80 | 1 |
| Increase in Treatment Seeking and Diagnosed Population Drives the Market | 80 | 1 |
| Restraints for the GERD Therapeutics Market | 80 | 1 |
| Declining Annual Cost of Therapy will Obstruct Market Growth | 80 | 1 |
| Low Unmet Needs Make the Market Less Attractive | 80 | 1 |
| Global Crohn s Disease Therapeutics Market Forecasts | 81 | 1 |
| Introduction | 81 | 1 |
| Revenue | 82 | 1 |
| Generic Share | 83 | 1 |
| Revenue Analysis by Country | 84 | 2 |
| Annual Cost of Treatment | 86 | 1 |
| Treatment Flow Algorithm | 87 | 1 |
| Treatment Usage Patterns | 88 | 1 |
| Diseased Population | 89 | 1 |
| Treatment Seeking Population | 89 | 1 |
| Diagnosed Population | 89 | 1 |
| Treated Population | 90 | 1 |
| Major Marketed Products | 90 | 1 |
| Remicade (infliximab) | 90 | 1 |
| Overview | 90 | 1 |
| Humira (adalimumab) | 90 | 1 |
| Overview | 90 | 1 |
| Tysabri (natalizumab) | 91 | 1 |
| Overview | 91 | 1 |
| Entocort EC (budenoside) | 91 | 1 |
| Overview | 91 | 1 |
| Cimzia (cetrolizumab pegol) | 91 | 1 |
| Overview | 91 | 1 |
| Drivers and Restraints for the Crohn s Disease Therapeutics Market | 92 | 1 |
| Drivers for the Crohn s Disease Therapeutics Market | 92 | 1 |
| Increasing Prevalence of the Disease Drives the Market | 92 | 1 |
| Existing High Priced Drugs and Future Approval of Biologics Fuel Market Growth | 92 | 1 |
| Higher Prescription Rate will have Positive Impact on the Market in the Future | 92 | 1 |
| Restraints for the Crohn s Disease Therapeutics Market | 93 | 1 |
| Low Diagnosis Rate Acts as a Barrier for the Market | 93 | 1 |
| Global Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis | 94 | 28 |
| Research and Development Pipeline by Phase | 94 | 1 |
| Research and Development Pipeline by Indication | 95 | 1 |
| Irritable Bowel Syndrome: Research and Development Pipeline | 96 | 1 |
| Overview | 96 | 1 |
| Pipeline by Clinical Phases of Development | 97 | 1 |
| Discovery | 97 | 1 |
| Preclinical | 97 | 1 |
| Phase I | 97 | 1 |
| Phase II | 98 | 1 |
| Phase III/NDA Filed | 98 | 1 |
| Promising Drugs under Clinical Development for Irritable Bowel Syndrome | 99 | 1 |
| Linaclotide (Linaclotide Acetate) | 99 | 1 |
| Overview | 99 | 1 |
| Efficacy | 99 | 1 |
| Safety | 99 | 1 |
| Clinical Study Details | 99 | 1 |
| Asimadoline | 100 | 1 |
| Overview | 100 | 1 |
| Efficacy | 100 | 1 |
| Safety | 100 | 1 |
| Clinical Trial Details | 101 | 1 |
| Xifaxan (Rifaximin) | 101 | 1 |
| Overview | 101 | 1 |
| Efficacy | 101 | 1 |
| Safety | 102 | 1 |
| Clinical Study Details | 102 | 1 |
| Ulcerative Colitis: Research and Development Pipeline | 103 | 1 |
| Overview | 103 | 1 |
| Pipeline by Clinical Phases of Development | 104 | 1 |
| Discovery | 104 | 1 |
| Preclinical | 104 | 1 |
| Phase I | 104 | 1 |
| Phase II | 105 | 1 |
| Phase III/NDA Filed | 106 | 1 |
| Promising Drugs under Clinical Development for Ulcerative Colitis | 107 | 1 |
| Humira (Adalimumab) | 107 | 1 |
| Overview | 107 | 1 |
| Efficacy | 107 | 1 |
| Safety | 107 | 1 |
| Clinical Study Details | 107 | 1 |
| Golimumab | 107 | 1 |
| Overview | 107 | 1 |
| Efficacy | 107 | 1 |
| Safety | 107 | 1 |
| Clinical Study Details | 108 | 1 |
| Vedolizumab | 108 | 1 |
| Overview | 108 | 1 |
| Efficacy | 108 | 1 |
| Safety | 108 | 1 |
| Clinical Study Details | 108 | 1 |
| Crohn s Disease: Research and Development Pipeline | 109 | 1 |
| Overview | 109 | 1 |
| Pipeline by Clinical Phases of Development | 110 | 1 |
| Discovery | 110 | 1 |
| Preclinical | 110 | 1 |
| Phase I | 110 | 1 |
| Phase II | 111 | 1 |
| Phase III | 112 | 1 |
| Promising Drugs under Clinical Development for Crohn s Disease | 113 | 1 |
| Myoconda | 113 | 1 |
| Overview | 113 | 1 |
| Efficacy | 113 | 1 |
| Safety | 113 | 1 |
| Clinical Study Details | 113 | 1 |
| Traficet-EN (CCX282) | 113 | 1 |
| Overview | 113 | 1 |
| Efficacy | 113 | 1 |
| Safety | 114 | 1 |
| Clinical Study Details | 114 | 1 |